Evoke Pharma (EVOK) Competitors $3.60 +0.16 (+4.49%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVOK vs. JATT, MTEX, NRSN, VYNE, CVM, PASG, SNYR, GELS, LEXX, and ALVRShould you be buying Evoke Pharma stock or one of its competitors? The main competitors of Evoke Pharma include JATT Acquisition (JATT), Mannatech (MTEX), NeuroSense Therapeutics (NRSN), VYNE Therapeutics (VYNE), CEL-SCI (CVM), Passage Bio (PASG), Synergy CHC Corp. (Uplisting) (SNYR), Gelteq (GELS), Lexaria Bioscience (LEXX), and AlloVir (ALVR). These companies are all part of the "pharmaceutical products" industry. Evoke Pharma vs. JATT Acquisition Mannatech NeuroSense Therapeutics VYNE Therapeutics CEL-SCI Passage Bio Synergy CHC Corp. (Uplisting) Gelteq Lexaria Bioscience AlloVir Evoke Pharma (NASDAQ:EVOK) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, valuation, profitability, risk, dividends, earnings and analyst recommendations. Do institutionals and insiders believe in EVOK or JATT? 48.0% of JATT Acquisition shares are owned by institutional investors. 2.3% of Evoke Pharma shares are owned by insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is EVOK or JATT more profitable? JATT Acquisition has a net margin of 0.00% compared to Evoke Pharma's net margin of -71.32%. JATT Acquisition's return on equity of -49.58% beat Evoke Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Evoke Pharma-71.32% -308.49% -53.66% JATT Acquisition N/A -49.58%2.84% Does the media refer more to EVOK or JATT? In the previous week, Evoke Pharma had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 1 mentions for Evoke Pharma and 0 mentions for JATT Acquisition. Evoke Pharma's average media sentiment score of 0.00 equaled JATT Acquisition'saverage media sentiment score. Company Overall Sentiment Evoke Pharma Neutral JATT Acquisition Neutral Which has stronger valuation and earnings, EVOK or JATT? JATT Acquisition has lower revenue, but higher earnings than Evoke Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvoke Pharma$10.25M0.54-$7.79M-$2.87-1.29JATT AcquisitionN/AN/A$6.85MN/AN/A Does the MarketBeat Community favor EVOK or JATT? Evoke Pharma received 360 more outperform votes than JATT Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformEvoke PharmaOutperform Votes36057.69% Underperform Votes26442.31% JATT AcquisitionN/AN/A SummaryJATT Acquisition beats Evoke Pharma on 6 of the 9 factors compared between the two stocks. Get Evoke Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVOK vs. The Competition Export to ExcelMetricEvoke PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.52M$6.48B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-0.349.0626.7119.71Price / Sales0.54251.50386.13120.55Price / CashN/A65.8538.2534.62Price / Book-0.406.456.774.50Net Income-$7.79M$143.98M$3.23B$248.22M7 Day Performance16.72%2.41%1.80%0.56%1 Month Performance48.00%4.56%11.10%13.17%1 Year Performance-31.63%-2.67%17.11%7.30% Evoke Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOKEvoke Pharma0.1066 of 5 stars$3.70+7.2%N/A-36.3%$5.52M$10.25M-0.344Negative NewsGap UpJATTJATT AcquisitionN/A$1.11-7.5%N/A-82.1%$19.15MN/A0.003High Trading VolumeMTEXMannatech1.1134 of 5 stars$9.93-5.9%N/A+34.0%$18.88M$117.87M-12.26250News CoverageAnalyst ForecastGap DownNRSNNeuroSense Therapeutics2.7009 of 5 stars$1.37+3.8%$14.00+921.9%+19.0%$18.72MN/A-2.1410VYNEVYNE Therapeutics1.9522 of 5 stars$1.22flat$6.25+412.3%-63.0%$18.56M$605,000.00-1.4230Analyst DowngradeGap UpHigh Trading VolumeCVMCEL-SCIN/A$0.20-8.6%N/A-88.5%$18.55MN/A-0.4243News CoverageGap DownHigh Trading VolumePASGPassage Bio2.0947 of 5 stars$0.30-1.3%$7.50+2,416.8%-76.5%$18.52MN/A-0.25130Gap UpSNYRSynergy CHC Corp. (Uplisting)2.5707 of 5 stars$2.11-11.3%$10.00+373.9%N/A$18.47M$34.83M0.0040Trending NewsEarnings ReportAnalyst RevisionGap DownGELSGelteqN/A$1.88-1.6%N/AN/A$17.74MN/A0.00N/APositive NewsLEXXLexaria Bioscience2.0166 of 5 stars$1.00-1.0%$7.00+600.0%-67.9%$17.74M$525,923.00-2.007ALVRAlloVirN/A$3.48-1.7%N/A-81.8%$17.55MN/A-0.17110Gap DownHigh Trading Volume Related Companies and Tools Related Companies JATT Alternatives MTEX Alternatives NRSN Alternatives VYNE Alternatives CVM Alternatives PASG Alternatives SNYR Alternatives GELS Alternatives LEXX Alternatives ALVR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVOK) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EVOK Stock Free EVOK Stock Alerts